Malaria vaccine (Crucell/GlaxoSmithKline)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMalaria vaccine (Crucell/GlaxoSmithKline)
Drug Alias NameReplication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01),Ad35-CS疟疾疫苗 - Crucell/葛兰素史克S/ASAd35.CS.01
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMalaria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesBurkina Faso
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcCrucell Holland Bv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcCrucell Holland BvNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsMalaria

Other Information

ATC CodeN/A
Related LinksN/A